CN104254543B - 用免疫球蛋白治疗粘膜炎 - Google Patents

用免疫球蛋白治疗粘膜炎 Download PDF

Info

Publication number
CN104254543B
CN104254543B CN201380013092.0A CN201380013092A CN104254543B CN 104254543 B CN104254543 B CN 104254543B CN 201380013092 A CN201380013092 A CN 201380013092A CN 104254543 B CN104254543 B CN 104254543B
Authority
CN
China
Prior art keywords
iga
mucositis
immunoglobulin
composition
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201380013092.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN104254543A (zh
Inventor
C·艾比
S·C·鲁尔
A·绍布
S·梅斯舍尔
A·祖尔舍尔
C·P·沃纳尔伯格
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universitaet Bern
CSL Behring AG
Original Assignee
Universitaet Bern
CSL Behring AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universitaet Bern, CSL Behring AG filed Critical Universitaet Bern
Publication of CN104254543A publication Critical patent/CN104254543A/zh
Application granted granted Critical
Publication of CN104254543B publication Critical patent/CN104254543B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/14—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from fungi, algea or lichens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CN201380013092.0A 2012-03-09 2013-03-08 用免疫球蛋白治疗粘膜炎 Active CN104254543B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12158939.4 2012-03-09
EP12158939.4A EP2636683A1 (en) 2012-03-09 2012-03-09 Treatment of mucositis with Immunoglobulin
PCT/EP2013/054722 WO2013132063A1 (en) 2012-03-09 2013-03-08 Treatment of mucositis with immunoglobulin

Publications (2)

Publication Number Publication Date
CN104254543A CN104254543A (zh) 2014-12-31
CN104254543B true CN104254543B (zh) 2018-06-05

Family

ID=45808320

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380013092.0A Active CN104254543B (zh) 2012-03-09 2013-03-08 用免疫球蛋白治疗粘膜炎

Country Status (10)

Country Link
US (1) US9546209B2 (enExample)
EP (2) EP2636683A1 (enExample)
JP (1) JP6238910B2 (enExample)
KR (1) KR102120620B1 (enExample)
CN (1) CN104254543B (enExample)
AU (1) AU2013201394B2 (enExample)
CA (1) CA2865810C (enExample)
DK (1) DK2822966T3 (enExample)
ES (1) ES2660157T3 (enExample)
WO (1) WO2013132063A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102142261B1 (ko) 2012-03-09 2020-08-11 체에스엘 베링 아게 분비형 면역글로불린을 포함하는 조성물
EP2636684A1 (en) * 2012-03-09 2013-09-11 CSL Behring AG Prevention of infection
EP2636681A1 (en) 2012-03-09 2013-09-11 CSL Behring AG Process for enriching IgA
CA3043012A1 (en) 2016-11-10 2018-05-17 Becton, Dickinson And Company Timeline system for monitoring a culture media protocol
EP4662233A1 (en) * 2023-01-13 2025-12-17 Michael R. Simon Process for preparation of secretory iga and secretory igm and use thereof for treating necrotizing enterocolitis

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6300104B1 (en) * 1997-06-19 2001-10-09 The Regents Of The University Of California Secretory immunoglobulin produced by single cells and methods for making and using same
WO2009046168A1 (en) * 2007-10-02 2009-04-09 Avaxia Biologics, Inc. Antibody therapy for use in the digestive tract

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1068871A1 (en) * 1999-07-07 2001-01-17 Jean-Paul Perraudin Novel methods and medicament for treating infections diseases involving microbial biofilms

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6300104B1 (en) * 1997-06-19 2001-10-09 The Regents Of The University Of California Secretory immunoglobulin produced by single cells and methods for making and using same
WO2009046168A1 (en) * 2007-10-02 2009-04-09 Avaxia Biologics, Inc. Antibody therapy for use in the digestive tract

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Topical curcumin can inhibit deleterious effects of upper respiratory tract bacteria on human oropharyngeal cells in vitro: potential role for patients with cancer therapy induced mucositis?;Sonja Lüer et al;《Support Care Cancer》;20100514;第19卷;799-806 *

Also Published As

Publication number Publication date
HK1204629A1 (en) 2015-11-27
DK2822966T3 (en) 2018-02-26
AU2013201394A1 (en) 2013-09-26
WO2013132063A1 (en) 2013-09-12
CA2865810C (en) 2022-09-06
EP2822966A1 (en) 2015-01-14
AU2013201394B2 (en) 2015-09-03
JP2015513554A (ja) 2015-05-14
ES2660157T3 (es) 2018-03-21
JP6238910B2 (ja) 2017-11-29
KR20140145587A (ko) 2014-12-23
US9546209B2 (en) 2017-01-17
CA2865810A1 (en) 2013-09-12
KR102120620B1 (ko) 2020-06-10
US20150030613A1 (en) 2015-01-29
CN104254543A (zh) 2014-12-31
EP2822966B1 (en) 2017-11-29
EP2636683A1 (en) 2013-09-11

Similar Documents

Publication Publication Date Title
RU2764981C1 (ru) Композиции и способы лечения и предупреждения инфекций, вызванных Staphylococcus aureus
EP3157565B1 (en) Treatment of polybacterials infections
CN104254543B (zh) 用免疫球蛋白治疗粘膜炎
CN104254542A (zh) 包含分泌-样免疫球蛋白的组合物
AU2017201201B2 (en) Treatment for dermatological pathologies
KR102167261B1 (ko) 관절염 치료
JP2025165988A (ja) プラスミノーゲンとの結合のための抗体
WO2004083425A1 (ja) 歯周病治療剤
HK1204629B (en) Treatment of mucositis with immunoglobulin a
HK40013773A (zh) 皮肤病学病状的治疗
JPWO2020018584A5 (enExample)
HK1187260A (en) Treatment for dermatological pathologies

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant